Xeltis AG is completing a financing round totalling EUR 27 million with Life Sciences Partners, Kurma Partners and VI Partners as the primary investors. Verium acted as shareholder representative, actively advising a number of investors as well as Xeltis

Zurich, 1. December 2014

In early December, Xeltis, a pioneer in medical technology, specialising in heart and vascular surgery, announced the successful completion of an oversubscribed Series B financing. Led by Life Sciences Partners, Amsterdam (LSP), and supported by institutional co-investors Kurma Partners, Paris (Kurma), and VI Partners, Zug (VI), as well as the current shareholders of Xeltis, the purpose of the financing is to obtain market approval for the company’s first product, a pulmonary valve replacement, and the continued development of the product pipeline.

Based on Nobel prize-winning technology, Xeltis develops synthetic, biodegradable heart valves and blood vessels (scaffolds) and has established a completely novel therapeutic category: endogenous tissue growth (ETG). The heart valves and blood vessels, e.g. the Xeltis pulmonary valve, enable the spontaneous growth of natural tissue through the body’s own healing response alone.

Chief Executive Officer Laurent Grandidier is pleased with this important milestone and the support of such outstanding investment firms in the healthcare industry. "Together we are able to achieve our ambitious goals and hopefully make a difference in the life of millions of patients at the same time".

Verium actively supported a number of shareholders as well as Xeltis AG.

More information: